Homoharringtonine Synergized with Gilteritinib Results in the Downregulation of Myeloid Cell Leukemia-1 by Upregulating UBE2L6 in FLT3-ITD-Mutant Acute Myeloid (Leukemia) Cell Lines

Figure 4

The combination of gilteritinib and HHT resulted in Mcl-1 degradation by upregulated UBE2L6 expression. (a, b) Volcano plot of differential mRNAs measured by microarray in MV4-11 cells treated with 9 nM of HHT and/or 2.5 nM of gilteritinib.(c) The mRNA expression of UBE2L6 was measured by qPCR in MV4-11 cells and Molm13 cells treated with HHT and/or gilteritinib at the indicated concentrations for 24 hours. (d) The mRNA expression of UBE2L6 was measured by qPCR in MV4-11 cells and Molm13 cells after siRNA transfection. (e) The protein level of UBE2L6 was measured by western blotting in MV4-11 cells (left panel) and Molm13 cells (right panel) after siRNA transfection. (f) Quantification of (e). (g, h) Cell viability of Molm13 (g) and MV4-11 cells (h) treated with gilteritinib and HHT after siRNA transfection. (i, j) Apoptosis rates of Molm13 (i) and MV4-11 cells (j) treated with gilteritinib and HHT after siRNA transfection. (k) Mcl-1, UBE2L6, and GAPDH protein levels of MV4-11 and Molm13 cells treated with gilteritinib and HHT after siRNA transfection. (l, m) Quantification of (k). Each group was compared with control group. , , and

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)